BioStock: Curasight starts 2022 off strong

It is safe to say that Q1 was eventful for Danish Curasight who expanded its clinical development portfolio with no fewer than two new indications. With a solid financial position and late-stage clinical development in four different cancer indications, the company sets itself up for quite an interesting year. BioStock contacted Curasight’s CEO Ulrich Krasilnikoff to get his view on the past quarter.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/06/curasight-starts-2022-off-strong

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se